NCT05149131 - A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer | Biotech Hunter

Enrollment

960

Participants

Timeline

Start Date

January 17, 2022

Primary Completion Date

August 16, 2022

Study Completion Date

August 16, 2022

Conditions

Metastatic Castration-sensitive Prostate Cancer

Interventions

DRUG

ADT (Eligard®*) with or without treatment intensification

"Abiraterone acetate (Zytiga®) Enzalutamide (Xtandi®) Apalutamide (Erleada®) Docetaxel (Taxotere®)~\*may be substituted with leuroprolide gel, buserelin, goserelin, triptorelin, histrelin, cyproterone or degarelix"

Trial Locations (1)

Unknown

Databases, Multiple Locations